使徒行者

从10年到4.5年 “钱塘造”创新药怎么把研发时间砍掉一半多？_我的网站

火影忍者

A |

Screenshot from video obtained by the Global Times on July 21, 2026 shows the transfer of injured Philippine personnel near Ren'ai Jiao, which was overseen and assisted by the China Coast Guard. Photo: Courtesy of the China Coast GuardThe Philippine military side has again claimed that resupplying its grounded warship at Ren'ai Jiao needs no foreign approval and resupply there is within its self-claimed so-called EEZ, while Philippine media acknowledged that 15 "safe" resupply missions were made over the past two years under a China-Philippines provisional arrangement.
Chinese experts warned on Wednesday that Manila should not mistake humanitarian accommodation for a concession and must bear the consequences if it scraps the arrangement.
Yang Xiao, a research fellow at the Institute of Peaceful Development under the Chinese Academy of Social Sciences, told the Global Times on Wednesday that the Philippine side's claims are fundamentally flawed from legal, historical and practical perspectives.
Ren'ai Jiao is an inherent part of China's Nansha Qundao, over which China has indisputable and complete sovereignty, Yang said, adding that it is legally untenable for the Philippines to claim that Ren'ai Jiao is part of its exclusive economic zone.
"The Philippines deliberately grounded the abandoned warship at Ren'ai Jiao in 1999 and repeatedly pledged to remove it and restore the reef, but has failed to honor those commitments for more than two decades. This itself constitutes a continuing violation of China's territorial sovereignty," Yang said.
This is not the first time the Philippines has denied seeking China's approval for resupply missions to Ren'ai Jiao. In April 2025, Chinese Foreign Ministry spokesperson Guo Jiakun responded to similar claims, saying that China's position on how to handle the current situation at Ren'ai Jiao is clear and consistent.
"First, by keeping its warship grounded at Ren'ai Jiao for decades running, the Philippines has been violating China's sovereignty and the Declaration on the Conduct of Parties in the South China Sea (DOC). We demand that the Philippines tow away the warship. Second, between now and when the warship is towed away, should the Philippines need to send living necessities, China is willing to allow it in a humanitarian spirit if the Philippines informs China in advance and after on-site verification is conducted. Third, if the Philippines were to send large amount of construction materials to the warship and attempt to build fixed facilities or permanent outpost, China will absolutely not accept it and will resolutely stop it in accordance with the law and regulations," said the spokesperson.
"This means that the Philippines' so-called '15 safe and incident-free resupply missions' were all made possible by China's humanitarian accommodation and strict oversight," Yang stressed. Each mission was reported in advance and allowed to proceed only after inspections confirmed no prohibited construction materials were aboard. The CCG intercepted any such materials through lawful measures, Yang said.
The Philippines' unilateral denial of its notification and inspection obligations while enjoying the arrangement's benefits amounts to a blatant breach of its commitments, the expert noted.
Yang also noted that Manila's narrative contains an obvious logical contradiction. If Philippine resupply missions were truly unimpeded, there would be no need for Manila to repeatedly claim that China had "blocked" its missions and call for international intervention. Yet if China had continuously "obstructed" the missions, the Philippines could not have completed 15 safe and incident-free resupply operations.
"Manila has simply manipulated its narrative to suit its publicity needs, portraying itself as a 'victim' when seeking international attention while touting smooth resupply operations and its own strength when seeking to project toughness. Its hype over the 15 resupply missions is essentially aimed at rallying domestic support and stoking confrontation internationally to conceal the reality that its illegal presence is tightly constrained," Yang said.
China's handling of the Ren'ai Jiao situation, meanwhile, has consistently reflected restraint and humanitarian considerations. According to a statement by the China Coast Guard (CCG) spokesperson on the transfer of injured personnel by the Philippine side, Jiang Lue, a CCG spokesperson, said that on the morning of July 21, out of humanitarian considerations, China allowed the Philippines to transfer injured personnel by small boats from the BRP Sierra Madre (LT-57), which has been illegally grounded at Ren'ai Jiao, to Philippine Coast Guard vessel 9702. The CCG questioned and verified the Philippine vessels and monitored the entire process.
The CCG will continue to carry out rights-protection and law enforcement operations in accordance with the law in the waters around Ren'ai Jiao to safeguard China's territorial sovereignty and maritime rights and interests, Jiang said.
Yang said, stressing that Manila's tough talk and one-sided claims cannot make up for its legal and moral shortcomings.
"Any attempt to permanently occupy Chinese islands and reefs, unilaterally tear up the understanding and continuously challenge China's territorial sovereignty runs counter to international law and the broader trend toward peace and development in the region and is ultimately doomed to fail," Yang added.
。 AI设计的口服减重药有望2028年底上市

钱塘区生物医药产值已突破500亿元近日，杭州德睿智药科技有限公司宣布完成累计5200万美元B轮融资。2026年1月，杭州医药港，德睿智药一款名叫MDR-001的口服减重药，以令全球医药界瞩目的速度，启动Ⅲ期临床试验，成为国内首个进入临床Ⅲ期的AI小分子新药。这家仅40多人的公司，把一款一类创新药从立项到推进至Ⅲ期临床的时间，压缩到了4.5年。而传统同行完成同样的路程，通常需要8到12年。

B | 不用“大海捞针”了2021年初，85后海归博士牛张明，带着计算机和生物制药2个硕士学位、5种AI算法语言，在钱塘区成立了德睿智药。当时，他就想好了：“要走一条和传统制药完全不同的路。”传统新药研发有多难？业内有个“双十定律”，即成功研发一款创新药，平均需要10年的时间和10亿美元的投入。面对超过10的60次方级别、近乎无限的成药化学空间，科学家们只能靠经验和反复试错，如同在茫茫大海里捞针。牛张明说：“过去的药物发现，靠大量实验、反复试错，不仅耗时间，成功率也低。现在用上AI，好比给每位科学家配了一个‘超级大脑’做助手。”2026年，德睿智药基于MDR-001的研发流程，搭建起了由多智能体驱动的全链条AI制药引擎MAP。这个平台覆盖靶点发现、分子设计、多目标优化、实验验证及临床试验全链条。

C | “药物分子就像精密的拼图，每个片段都决定着药效和安全性。

D | 以往，这全靠科研人员的经验和反复试错。”牛张明解释，“MAP能通过学习海量已知药物的成功与失败案例，自动预测分子片段的性质，大幅减少试错成本、缩短研发周期。

E | ”他打了一个比方：“你可以把它想象成一位高效且永不疲倦的‘分子组装专家’，在虚拟世界里高速筛选，帮研发人员提前排除大量‘错误选项’。

F | ”药物研发，就这样从“大海捞针”变成了“高清导航”。口服减重新药将于2028年底上市MDR-001是一款GLP-1（胰高血糖素样肽-1）受体激动剂，与市面上常见的减肥注射剂最大的不同在于，它可以口服。“我们立项时，口服GLP-1还没有出现。口服小分子药物的依从性更高，患者不需要消毒针头注射、不需要低温冷藏保存，使用更方便；在某些适应证上疗效甚至优于注射剂型。”牛张明说。在MDR-001项目中，团队仅耗时8个月、实际仅合成80个小分子，就获得了高质量的临床前候选药物。